Study of MB07811 in Subjects With Hypercholesterolemia

Summary

A Phase 2 randomized, placebo controlled study assessing the efficacy, safety, and tolerability of MB07811 given orally to subjects with primary hypercholesterolemia for 12 weeks followed by a 6-week off drug phase.

Timeline

Start

2009-04

Primary completion

2009-12

Completion

2009-12

Outcome

Outcome not reported

Stopped: “Study terminated prior to initiation”

Drugs

Indications